Results for "hypertension"
Sodium Nutrition
Sodium nutrition examines how dietary sodium influences human health, covering sources, recommended intakes, physiological roles, and the risks of excess or deficiency.
Health & MedicineHeart Failure
** Heart failure (HF), also called congestive heart failure (CHF), is a clinical syndrome in which the heart cannot pump enough blood to meet the body’s metabolic needs or does so only at the cost of elevated filling pressures. **CONTENT:** ## Overview Heart failure is not a single disease but a **syndrome** that results from structural or functional cardiac abnormalities that impair the heart’s ability to **fill** (diastolic dysfunction) or **eject** (systolic dysfunction) blood efficiently. The condition may develop gradually over years, as in chronic hypertension or coronary artery disease, or present abruptly after a massive myocardial infarction. Patients typically experience **dyspnea**, **fatigue**, **edema**, and reduced exercise tolerance, reflecting the body’s attempt to compensate for inadequate circulation. Compensatory mechanisms—such as activation of the renin‑angiotensin‑aldosterone system (RAAS) and sympathetic nervous system—temporarily preserve perfusion but eventually lead to maladaptive remodeling, worsening the heart’s performance. HF is classified by **ejection fraction (EF)**: - **HF with reduced EF (HFrEF)**: EF ≤ 40%, reflecting impaired systolic contraction. - **HF with preserved EF (HFpEF)**: EF ≥ 50%, where diastolic filling is the primary problem. - **HF with mildly reduced EF (HFmrEF)**: EF 41‑49%, an intermediate category. Because symptoms overlap with many other conditions, a thorough evaluation—including history, physical exam, **echocardiography**, natriuretic peptide testing, and sometimes cardiac MRI—is essential. **If you experience persistent shortness of breath, swelling of the ankles, or unexplained fatigue, seek medical evaluation promptly**, as early diagnosis improves outcomes. ## History/Background The concept of “heart failure” dates back to ancient Greek physicians such as **Hippocrates**, who described “dropsy” (fluid accumulation) as a sign of a weak heart. In the 19th century, **William Osler** coined the term “congestive heart failure” after observing pulmonary congestion in patients with advanced cardiac disease. The invention of the **electrocardiogram (ECG)** in the early 1900s and the development of **cardiac catheterization** in the 1940s allowed clinicians to measure cardiac pressures directly, confirming the hemodynamic basis of HF. A pivotal moment arrived in the 1970s with the **Framingham Heart Study**, which identified hypertension, myocardial infarction, and valvular disease as major risk factors. The 1980s saw the first large‑scale trials of **ACE inhibitors** (e.g., enalapril) demonstrating mortality reduction, establishing pharmacologic blockade of the RAAS as a cornerstone of therapy. The 1990s introduced **beta‑blockers** and **spironolactone**, further improving survival. More recent milestones include the **PARADIGM‑HF trial (2014)** showing the benefit of the angiotensin‑neprilysin inhibitor sacubitril/valsartan, and the **2021 FDA approval of SGL‑inhibitors** (e.g., dapagliflozin) for HF regardless of diabetes status. ## Key Information - **Epidemiology:** Over 64 million people worldwide live with HF; prevalence rises sharply after age 65. In the United States, HF accounts for ~1 million hospitalizations annually and a 5‑year mortality of ~50 % after diagnosis. - **Etiology:** Common causes include ischemic heart disease, hypertension, cardiomyopathies (dilated, hypertrophic, restrictive), valvular lesions, and arrhythmias. Lifestyle factors—obesity, excessive alcohol, and uncontrolled diabetes—also contribute. - **Diagnostic Criteria:** The **2022 ACC/AHA/HFSA guideline** emphasizes a combination of symptoms, signs, and objective evidence of cardiac dysfunction (e.g., EF < 50 % or elevated natriuretic peptides). - **Management:** A multi‑modal approach is standard: 1. **Pharmacologic therapy**—ACE inhibitors/ARBs/ARNI, beta‑blockers, mineralocorticoid receptor antagonists, SGL‑inhibitors, and diuretics for volume control. 2. **Device therapy**—implantable cardioverter‑defibrillators (ICDs) for sudden death prevention, cardiac resynchronization therapy (CRT) for dyssynchrony, and left ventricular assist devices (LVADs) for end‑stage disease. 3. **Lifestyle interventions**—salt restriction, fluid limitation, regular aerobic exercise, smoking cessation, and weight management. 4. **Advanced care**—heart transplantation or palliative care when refractory. - **Prognosis:** Early, guideline‑directed therapy can reduce mortality by 30‑40 % and improve quality of life. However, recurrent hospitalizations remain common, underscoring the need for close follow‑up and patient education. ## Significance Heart failure represents a **major public health challenge** due to its high prevalence, costly hospitalizations, and substantial morbidity. Economically, HF accounts for an estimated **$30 billion** in annual U.S. healthcare expenditures, with a growing burden as populations age. Clinically, HF serves as a **sentinel indicator** of underlying cardiovascular disease, prompting aggressive risk‑factor modification that benefits overall heart health. Advances in pharmacology, device engineering, and telemonitoring have transformed HF from a uniformly fatal condition into a manageable chronic disease for many patients. Nonetheless, disparities persist—racial and socioeconomic groups experience higher incidence and poorer outcomes, highlighting the need for equitable access to care and culturally competent education. **When to seek professional care:** If you notice new or worsening shortness of breath (especially when lying flat), sudden weight gain (> 2 kg in a few days), swelling of the legs or abdomen, or a persistent cough, contact a healthcare provider immediately. Early intervention can prevent decompensation and reduce the risk of life‑threatening complications. **INFOBOX:** - Name: Heart Failure (Congestive Heart Failure) - Type: Cardiovascular syndrome / Chronic disease - Date: First described as “congestive heart failure” in the late 19th century (circa 1885) - Location: Global (affects populations worldwide) - Known For: Impaired cardiac filling and/or ejection leading to systemic and pulmonary congestion **TAGS:** heart failure, congestive heart failure, cardiology, ejection fraction, hypertension, myocardial infarction, ACE inhibitors, cardiac remodeling
Health & MedicineCoronary Artery Disease
Coronary artery disease (CAD) is a condition where the buildup of atheromatous plaque in the coronary arteries leads to reduced blood flow to the heart muscle, increasing the risk of heart attacks and other cardiovascular events. ## Overview Coronary artery disease (CAD) is a widespread and complex condition affecting millions worldwide. It involves the narrowing of the coronary arteries due to the accumulation of cholesterol-rich atheromatous plaque, which can lead to reduced blood flow to the heart muscle, causing various symptoms and potentially life-threatening complications. CAD is the most common cause of cardiovascular disease, responsible for a significant number of deaths and hospitalizations globally. CAD occurs when the walls of the coronary arteries become damaged, allowing low-density lipoprotein (LDL) cholesterol to accumulate and form atheromatous plaques. These plaques can rupture, triggering an inflammatory response that further damages the artery wall, leading to a blockage or significant narrowing of the coronary arteries. The reduced blood flow can cause a range of symptoms, from stable angina and myocardial ischemia to life-threatening myocardial infarctions (heart attacks). ## History/Background The concept of CAD dates back to the 19th century, when the French pathologist Claude Bernard first described the condition. However, it wasn't until the 1920s that the role of atherosclerosis in CAD became more widely recognized. The development of coronary angiography in the 1950s revolutionized the diagnosis and treatment of CAD, allowing doctors to visualize the coronary arteries and identify blockages. Since then, numerous advances in medical technology and our understanding of CAD have led to improved treatments and outcomes for patients. ## Key Information ### Risk Factors - **Hypertension**: High blood pressure is a significant risk factor for CAD, as it can cause damage to the coronary arteries and increase the risk of plaque buildup. - **High Cholesterol**: Elevated levels of LDL cholesterol can contribute to atheromatous plaque formation and increase the risk of CAD. - **Smoking**: Smoking is a well-established risk factor for CAD, as it damages the cardiovascular system and increases inflammation. - **Diabetes**: People with diabetes are at increased risk of CAD due to the damage caused by high blood sugar levels to the cardiovascular system. - **Family History**: A family history of CAD can increase an individual's risk of developing the condition. ### Symptoms and Complications - **Stable Angina**: A feeling of chest tightness or pressure that occurs when the heart muscle is not receiving enough oxygen. - **Unstable Angina**: A more severe and unpredictable form of angina that can indicate a greater risk of heart attack. - **Myocardial Ischemia**: A condition where the heart muscle is not receiving enough oxygen, which can lead to damage or death of heart tissue. - **Myocardial Infarction (Heart Attack)**: A life-threatening condition where the heart muscle is severely damaged due to a blockage in the coronary artery. ### Diagnosis and Treatment - **Coronary Angiography**: A test that uses X-rays to visualize the coronary arteries and identify blockages. - **Coronary Artery Bypass Grafting (CABG)**: A surgical procedure that involves bypassing blockages in the coronary arteries with a healthy graft. - **Percutaneous Coronary Intervention (PCI)**: A minimally invasive procedure that involves using a catheter to widen a narrowed coronary artery. - **Statins**: Medications that lower LDL cholesterol and reduce the risk of CAD. - **Aspirin**: A medication that helps prevent blood clots and reduces the risk of heart attack. ## Significance CAD is a widespread and complex condition that affects millions worldwide, resulting in significant morbidity and mortality. Understanding the risk factors, symptoms, and treatment options for CAD is crucial for preventing and managing the condition. Early detection and treatment can significantly reduce the risk of complications and improve outcomes for patients. INFOBOX: - Name: **Coronary Artery Disease** - Type: Cardiovascular Disease - Date: 19th century (first described by Claude Bernard) - Location: Global - Known For: Most common cause of cardiovascular disease and leading cause of death worldwide TAGS: Coronary artery disease, cardiovascular disease, atherosclerosis, heart attack, myocardial infarction, angina, hypertension, high cholesterol, smoking, diabetes, family history.
Health & MedicinePotassium Nutrition
Potassium nutrition refers to the intake, metabolism, and physiological roles of the essential mineral potassium, a key electrolyte that supports cellular function, fluid balance, and cardiovascular health.
Health & MedicineBlood Vessels
** Blood vessels are the intricate network of arteries, veins, and capillaries that transport blood throughout the body, delivering oxygen and nutrients while removing waste products. **CONTENT:** ## Overview Blood vessels form a **closed circulatory system** that sustains every organ and tissue in the human body. The system is composed of three primary vessel types: **arteries**, which carry oxygen‑rich blood away from the heart; **veins**, which return deoxygenated blood toward the heart; and **capillaries**, microscopic channels where exchange of gases, nutrients, and waste occurs. Together, these vessels maintain **hemodynamic stability**, regulate blood pressure, and support immune surveillance. Their walls are specialized: arteries possess thick, elastic layers to withstand high pressure, veins contain valves to prevent backflow, and capillaries consist of a single endothelial cell layer to facilitate diffusion. Understanding blood vessel anatomy and physiology is essential for recognizing common vascular disorders such as hypertension, atherosclerosis, and deep‑vein thrombosis. While this article provides a scientific overview, any unexplained pain, swelling, discoloration, or sudden changes in circulation should prompt a consultation with a qualified healthcare professional. Early evaluation can prevent complications and guide appropriate treatment. ## History/Background The study of blood vessels dates back to ancient civilizations; **Hippocrates** (c. 460–370 BC) described the pulse as a sign of arterial flow, while **Galen** (129–c. 200 AD) proposed that arteries carried “vital spirits.” The modern understanding began in the 16th century when **Andreas Vesalius** illustrated detailed vascular anatomy in *De humani corporis fabrica* (1543). In 1628, **William Harvey** revolutionized physiology with his work *De Motu Cordis*, demonstrating that blood circulates continuously in a closed loop driven by the heart. The 19th century saw the invention of the **microscope**, allowing scientists like **Camillo Golgi** to visualize capillaries and the **endothelial lining**. The 20th century introduced imaging breakthroughs—angiography (1927), Doppler ultrasound (1960s), and magnetic resonance angiography (1990s)—which transformed diagnostic capabilities and surgical planning. ## Key Information - **Arterial Structure:** Consists of three layers—tunica intima (endothelium), tunica media (smooth muscle and elastic fibers), and tunica adventitia (connective tissue). The **elastic arteries** (e.g., aorta) buffer pulsatile flow, while **muscular arteries** (e.g., femoral) regulate distribution via vasoconstriction and vasodilation. - **Venous Structure:** Thinner walls, larger lumen, and **valves** in the lower extremities prevent gravitational pooling. **Portal veins** (e.g., hepatic portal) direct blood from gastrointestinal organs to the liver for metabolism. - **Capillary Types:** **Continuous capillaries** (most tissues) have uninterrupted endothelium; **fenestrated capillaries** (kidney glomeruli, endocrine glands) possess pores for rapid exchange; **sinusoidal capillaries** (liver, spleen, bone marrow) have larger gaps for cells and proteins. - **Regulation of Blood Flow:** Autonomic nervous system, local metabolites (e.g., nitric oxide), and hormonal signals (e.g., angiotensin II) modulate vessel diameter. **Baroreceptors** in carotid sinus and aortic arch detect pressure changes, triggering reflex adjustments. - **Common Pathologies:** - **Atherosclerosis:** Lipid‑laden plaques narrow arteries, increasing risk of myocardial infarction and stroke. - **Hypertension:** Chronic elevation of arterial pressure damages vessel walls, leading to aneurysms or renal disease. - **Varicose Veins:** Valve failure causes venous dilation and discomfort. - **Peripheral Artery Disease (PAD):** Obstructed arterial flow to limbs, causing claudication. - **Diagnostic Tools:** Non‑invasive methods (ultrasound, CT angiography) and invasive angiography help visualize vessel patency, wall integrity, and flow dynamics. **When to Seek Care:** Sudden chest pain, unexplained limb swelling, persistent headaches, or changes in skin color may signal vascular emergencies. Prompt medical evaluation is crucial. ## Significance Blood vessels are fundamental to **homeostasis**, enabling oxygen delivery, nutrient transport, thermoregulation, and waste removal. Their dysfunction underlies many leading causes of morbidity and mortality worldwide, including heart disease, stroke, and chronic kidney disease. Advances in vascular biology have spurred life‑saving interventions: **angioplasty**, **stent placement**, **bypass grafting**, and **endovascular aneurysm repair** have transformed outcomes for patients with obstructive or aneurysmal disease. Moreover, research into **angiogenesis**—the formation of new vessels—holds promise for regenerative medicine, cancer therapy, and tissue engineering. Understanding the structure and function of blood vessels thus remains a cornerstone of both clinical practice and biomedical innovation. **INFOBOX:** - Name: Blood Vessels - Type: Anatomical/Physiological System - Date: Conceptualized as a closed circulatory system in 1628 (William Harvey) - Location: Throughout the human body (systemic and pulmonary circuits) - Known For: Transporting blood, regulating pressure, and facilitating exchange of gases, nutrients, and waste **TAGS:** circulatory system, arteries, veins, capillaries, vascular biology, hypertension, atherosclerosis, medical imaging
Health & MedicineMetabolic Syndrome
** Metabolic syndrome is a cluster of interrelated risk factors—abdominal obesity, elevated blood pressure, high fasting glucose, high triglycerides, and low HDL cholesterol—that together markedly increase the risk of cardiovascular disease, type 2 diabetes, and premature death. **CONTENT:** ## Overview Metabolic syndrome (MetS) describes a **multifactorial metabolic disturbance** in which three or more of five classic components coexist: **central (abdominal) obesity**, **elevated blood pressure**, **hyperglycemia**, **hypertriglyceridemia**, and **low high‑density lipoprotein (HDL) cholesterol**. The syndrome reflects underlying insulin resistance and chronic low‑grade inflammation, which together drive a cascade of vascular and metabolic damage. Individuals with MetS are two‑ to three‑fold more likely to develop atherosclerotic cardiovascular disease (ASCVD) and up to five‑fold more likely to progress to type 2 diabetes mellitus (T2DM). The diagnostic criteria differ slightly among major health organizations (e.g., the National Cholesterol Education Program Adult Treatment Panel III, the International Diabetes Federation), but all require the presence of at least three of the five risk factors. Because the components are modifiable, early identification offers a valuable window for lifestyle and pharmacologic interventions that can reverse or blunt disease progression. ## History/Background The concept of a “syndrome” linking obesity, hypertension, dyslipidemia, and glucose intolerance emerged in the 1970s when researchers noted a high prevalence of these abnormalities among patients with coronary artery disease. In 1988, **J. Reaven** coined the term **“Syndrome X”** to emphasize the central role of insulin resistance. The National Cholesterol Education Program (NCEP) formalized diagnostic thresholds in 2001 with the **Adult Treatment Panel III (ATP‑III)** guidelines, which remain widely used. The International Diabetes Federation (IDF) later refined the definition in 2005, adding ethnic‑specific waist‑circumference cut‑offs to improve global applicability. Over the past three decades, epidemiologic studies have shown a steady rise in MetS prevalence, paralleling worldwide increases in obesity and sedentary lifestyles. ## Key Information - **Diagnostic thresholds (ATP‑III):** 1. **Waist circumference** ≥ 102 cm (men) or ≥ 88 cm (women). 2. **Triglycerides** ≥ 150 mg/dL (1.7 mmol/L) or drug treatment. 3. **HDL‑C** < 40 mg/dL (men) or < 50 mg/dL (women) or drug treatment. 4. **Blood pressure** ≥ 130/85 mm Hg or antihypertensive therapy. 5. **Fasting glucose** ≥ 100 mg/dL (5.6 mmol/L) or glucose‑lowering medication. - **Pathophysiology:** Central obesity leads to excess free fatty acids and adipokine secretion, fostering insulin resistance. Insulin resistance impairs glucose uptake, raises hepatic VLDL production (raising triglycerides), and reduces HDL synthesis. Simultaneously, sympathetic overactivity and endothelial dysfunction raise blood pressure. - **Risk quantification:** The presence of MetS adds an estimated **20–30 % absolute increase** in 10‑year ASCVD risk beyond traditional calculators. - **Management:** First‑line therapy emphasizes **lifestyle modification**—weight loss of 5–10 % of body weight, ≥150 minutes/week of moderate‑intensity aerobic activity, and a Mediterranean‑style diet rich in fruits, vegetables, whole grains, nuts, and olive oil. Pharmacologic treatment targets individual components: statins for dyslipidemia, ACE inhibitors/ARBs for hypertension, metformin or newer agents (GLP‑1 receptor agonists, SGLT2 inhibitors) for hyperglycemia, and, when needed, fibrates or omega‑3 fatty acids for triglycerides. - **Screening recommendations:** Adults ≥ 20 years should be screened for waist circumference and fasting glucose at least every 3–5 years, with more frequent testing for those with overweight/obesity or a family history of diabetes or ASCVD. - **When to seek professional care:** If you notice rapid weight gain around the abdomen, persistent high blood pressure readings, fasting glucose ≥ 100 mg/dL, or abnormal lipid results on a routine blood test, schedule an appointment with a primary‑care provider. Early evaluation can prevent progression to heart attack, stroke, or diabetes. ## Significance Metabolic syndrome is a **public health priority** because it aggregates multiple modifiable risk factors into a single, high‑risk phenotype. Its rising prevalence—estimated at **20–30 % of adults in many high‑income countries** and climbing in low‑ and middle‑income nations—places a substantial burden on healthcare systems through increased hospitalizations, medication costs, and loss of productivity. Recognizing MetS shifts clinical focus from treating isolated abnormalities to addressing the **underlying insulin‑resistant state**, fostering more holistic preventive strategies. Moreover, research into the syndrome has spurred advances in understanding adipose tissue biology, the gut‑microbiome’s role in metabolism, and the therapeutic potential of novel agents that improve insulin sensitivity and cardiovascular outcomes. By integrating lifestyle counseling, risk‑factor‑specific drugs, and emerging therapies, clinicians can markedly reduce the long‑term complications associated with MetS, underscoring the importance of early detection and sustained management. **INFOBOX:** - **Name:** Metabolic Syndrome (also known as Syndrome X or Insulin‑Resistance Syndrome) - **Type:** Clinical syndrome / metabolic disorder - **Date:** First described as “Syndrome X” in 1988; formal diagnostic criteria established 2001 (ATP‑III) - **Location:** Global (prevalence varies by region, ethnicity, and socioeconomic status) - **Known For:** Clustering of abdominal obesity, hypertension, hyperglycemia, hypertriglyceridemia, and low HDL cholesterol, markedly increasing cardiovascular and diabetes risk **TAGS:** metabolic syndrome, insulin resistance, cardiovascular disease, type 2 diabetes, obesity, hypertension, dyslipidemia, public health
Health & MedicineSmooth Muscle
** Smooth muscle is an involuntary, non‑striated muscle type that lines hollow organs and blood vessels, regulating tone, flow, and movement throughout the body. **CONTENT:** ## Overview **Smooth muscle** is one of the three major muscle classifications in the human body, alongside skeletal and cardiac muscle. Unlike skeletal muscle, which is under conscious control and displays a striped (striated) appearance, smooth muscle fibers are spindle‑shaped, lack visible striations, and contract without voluntary input. These cells are organized into sheets or bundles that line the walls of hollow structures such as the gastrointestinal tract, urinary bladder, uterus, respiratory airways, and the tunica media of most blood vessels. Their primary function is to generate slow, sustained contractions that regulate lumen diameter, propel contents, and maintain vascular resistance. Smooth muscle contraction is driven by intracellular calcium ions that bind to the protein **calmodulin**, activating **myosin light‑chain kinase (MLCK)**, which phosphorylates myosin heads and permits cross‑bridge cycling with actin filaments. This calcium‑calmodulin‑MLCK pathway allows smooth muscle to respond to a wide array of stimuli, including neural (autonomic), hormonal (e.g., oxytocin, vasopressin), and local metabolic signals (e.g., nitric oxide). Because the contractile apparatus is not anchored to a rigid sarcomere, smooth muscle can maintain tension for extended periods with minimal energy expenditure—a property known as the “latch state.” Clinically, disorders of smooth muscle manifest as dysmotility (e.g., irritable bowel syndrome), vascular tone abnormalities (e.g., hypertension, vasospasm), or obstetric complications (e.g., preterm labor). Understanding smooth muscle physiology is essential for developing therapies that target its unique signaling pathways. ## History/Background The existence of a non‑striated muscle was first noted in the 19th century when anatomists such as **Johannes Müller** described “involuntary muscle” in the walls of hollow organs. In 1855, **Rudolf Virchow** coined the term “smooth muscle” to distinguish it from the striated fibers of skeletal muscle. Early physiological experiments by **Walter Cannon** in the early 1900s demonstrated that smooth muscle could contract in response to autonomic stimulation, laying the groundwork for modern neuro‑vascular research. The discovery of the calcium‑calmodulin‑MLCK cascade in the 1970s by **M. A. R. H. G. R.** (R. A. G. R. stands for R. A. G. R. – actually the key scientists were R. A. R. and colleagues) revolutionized our molecular understanding and opened avenues for pharmacologic modulation, such as calcium channel blockers and phosphodiesterase inhibitors. ## Key Information - **Structure:** Spindle‑shaped cells, 3–8 µm in diameter, with a single central nucleus; actin and myosin filaments are arranged in a criss‑cross pattern rather than in sarcomeres. - **Control:** Predominantly **autonomic nervous system** (sympathetic and parasympathetic) and **hormonal** regulation; also responsive to local factors like pH, oxygen tension, and stretch. - **Contraction Mechanism:** Intracellular Ca²⁺ → calmodulin → MLCK → phosphorylation of myosin light chains → cross‑bridge cycling; dephosphorylation by **myosin light‑chain phosphatase (MLCP)** leads to relaxation. - **Types:** *Single‑unit* (visceral) smooth muscle, where cells are electrically coupled via gap junctions (e.g., gastrointestinal tract); *multi‑unit* smooth muscle, where cells act independently (e.g., iris, large arteries). - **Physiological Roles:** Peristalsis in the gut, urine storage and voiding, uterine contraction during labor, regulation of blood pressure via arterial tone, bronchiole diameter control, and pupil size adjustment. - **Pathology:** Hypertension (excessive vascular smooth muscle tone), asthma (bronchial smooth muscle hyper‑responsiveness), achalasia (failure of esophageal sphincter relaxation), and uterine atony (post‑partum hemorrhage). - **Therapeutics:** Calcium channel blockers (e.g., amlodipine), β‑adrenergic agonists (e.g., albuterol), nitric oxide donors, and oxytocin antagonists target smooth muscle pathways. ## Significance Smooth muscle’s ability to sustain tonic contraction with low energy demand makes it a cornerstone of circulatory and digestive homeostasis. Its dysregulation contributes to some of the most prevalent chronic diseases—hypertension, asthma, and gastrointestinal motility disorders—affecting millions worldwide. Research into smooth muscle signaling continues to yield novel drug classes that improve quality of life and reduce mortality. Moreover, the unique “latch state” inspires bio‑engineering efforts to design artificial tissues and smart biomaterials that mimic natural contractility. For anyone experiencing unexplained abdominal pain, persistent hypertension, or respiratory difficulty, consulting a healthcare professional is essential, as these symptoms may reflect underlying smooth muscle dysfunction. **NOTE:** This article provides general information and is not a substitute for professional medical advice. If you suspect a problem related to smooth muscle (e.g., severe abdominal cramps, uncontrolled high blood pressure, or breathing difficulties), seek evaluation from a qualified clinician promptly. **INFOBOX:** - Name: Smooth Muscle (non‑striated involuntary muscle) - Type: Muscular tissue - Date: First described as “smooth muscle” in 1855 - Location: Walls of hollow organs, blood vessels, respiratory tract, uterus, and other visceral structures - Known For: Generating sustained, low‑energy contractions that regulate lumen diameter and organ motility **TAGS:** smooth muscle, involuntary muscle, vascular tone, gastrointestinal motility, calcium signaling, autonomic nervous system, hypertension, asthma
Health & MedicineConditions Encyclopedia Entry 1779046085
The **Conditions Encyclopedia Entry 1779046085** refers to a comprehensive collection of medical conditions, providing in-depth information on various diseases, disorders, and health-related topics, serving as a valuable resource for both medical professionals and the general public.
Health & MedicineConditions Encyclopedia Entry 1778228601
This article provides a comprehensive overview of **Hypertension**, a common medical condition characterized by elevated blood pressure, its history, key information, significance, and importance of seeking professional care.
Health & MedicineConditions Encyclopedia Entry 1777820538
** Congenital Adrenal Hyperplasia (CAH) is a rare genetic disorder that affects the adrenal glands, leading to hormone imbalances and various physical and developmental issues. **CONTENT:** ### Overview Congenital Adrenal Hyperplasia (CAH) is a group of inherited disorders that affect the production of hormones in the adrenal glands. The adrenal glands produce essential hormones, such as cortisol and aldosterone, which regulate various bodily functions, including metabolism, blood pressure, and electrolyte balance. In CAH, the adrenal glands produce excessive amounts of androgens (male hormones), leading to a range of symptoms and complications. CAH is a relatively rare condition, affecting approximately 1 in 18,000 births. CAH is caused by mutations in the genes responsible for producing enzymes involved in hormone production. These mutations lead to a deficiency in the production of cortisol and aldosterone, causing the adrenal glands to overproduce androgens. The severity of CAH varies depending on the specific enzyme deficiency and the individual's genetic makeup. Some individuals may experience mild symptoms, while others may require life-long medical treatment. ### History/Background The first reported case of CAH dates back to 1920, when a British physician, Lawson Wilkins, described a child with ambiguous genitalia and excessive hair growth. Since then, numerous studies have shed light on the genetic and hormonal mechanisms underlying CAH. In the 1950s and 1960s, researchers identified the enzymes responsible for cortisol and aldosterone production, leading to the development of diagnostic tests and treatments for CAH. ### Key Information CAH is typically diagnosed in infancy or early childhood, although some cases may go undiagnosed until later in life. The symptoms of CAH can vary widely, depending on the severity of the enzyme deficiency and the individual's sex. Common symptoms include: * Ambiguous genitalia in females * Excessive hair growth and acne in both males and females * Early puberty in females * Short stature and delayed puberty in males * Hypertension and electrolyte imbalances CAH can be treated with hormone replacement therapy, which involves administering synthetic hormones to replace the deficient hormones. In some cases, surgery may be necessary to correct genital abnormalities or to remove excess adrenal tissue. ### Significance CAH is a significant condition that affects not only the individual but also their family and caregivers. Early diagnosis and treatment are crucial in preventing long-term complications and improving quality of life. CAH has also led to significant advances in our understanding of hormone production and regulation, which have far-reaching implications for the treatment of other endocrine disorders. **INFOBOX:** - **Name:** Congenital Adrenal Hyperplasia (CAH) - **Type:** Genetic disorder - **Date:** 1920 (first reported case) - **Location:** Global - **Known For:** Rare genetic disorder affecting hormone production and regulation **TAGS:** Congenital Adrenal Hyperplasia, genetic disorder, hormone imbalance, adrenal glands, enzyme deficiency, hormone replacement therapy, ambiguous genitalia, early puberty, hypertension, electrolyte imbalance.